Your browser doesn't support javascript.
loading
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen, Mogens K; Madsen, Christine V; Dehlendorff, Christian; Jakobsen, Anders; Johansen, Julia S; Steffensen, Karina D.
Affiliation
  • Boisen MK; *Department of Oncology, University of Copenhagen Herlev Hospital, Herlev; †Department of Oncology, Vejle Hospital, Vejle; ‡Danish Cancer Society, Danish Cancer Society Research Center, Copenhagen; §Department of Medicine, University of Copenhagen Herlev Hospital, Herlev; and ∥Faculty of Health and Medical Sciences, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Int J Gynecol Cancer ; 26(8): 1390-8, 2016 10.
Article in En | MEDLINE | ID: mdl-27648712

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplasms, Glandular and Epithelial / Bevacizumab / Chitinase-3-Like Protein 1 / Antineoplastic Agents, Immunological Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplasms, Glandular and Epithelial / Bevacizumab / Chitinase-3-Like Protein 1 / Antineoplastic Agents, Immunological Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Country of publication: